Tuesday 3rd July 2018
|Text too small?|
Orion Health Group said UK-based private equity firm Hg will acquire its Rhapsody business for $205 million and take a quarter stake in its Population Health unit for $20 million, leaving the New Zealand company in 100 percent control of just its hospitals division.
The transactions were outlined in a statement to the NZX and follow a strategic review by Auckland-based Orion that started in April last year. Of the $205 million, Orion will immediately use some $28 million to acquire about 25 percent of Rhapsody and $12 million to reinvest in a controlling stake in its Population Health unit while providing a net $30 million of cash to fund ongoing operations. After the transactions, Hg will own about 75 percent of Rhapsody and Orion will own 25 percent, while Orion will hold 75 percent of Population Health and Hg 25 percent.
The balance of the proceeds will be used by healthcare software developer Orion to fund a share buyback and provide funding for the remaining Hospitals division, it said. McCrae Ltd, Orion's biggest shareholder at 49.75 percent and the investment vehicle of chief executive Ian McCrae, will participate in the buyback in respect of 20 percent of its shares.
McCrae will vote its shares in favour of the transaction. As well as shareholder approval, the deal needs clearance from the Overseas Investment Office. A shareholder vote of the Hg deal and the buyback is expected to be held by late September, it said. They will be furnished with an independent report from KordaMentha.
“This investment provides Orion Health with a tremendous opportunity to deliver on our vision for customers, our people and for the healthcare sector,” CEO McCrae said. "We received strong interest in Orion Health’s business throughout the strategic review process and the board and I believe that Hg is the right partner to accelerate the expansion of Rhapsody and support our vision for Population Health."
Hg would make the investment via its Mercury 2 Fund, Orion said.
Hg's proposal values Orion at an enterprise value of $255 million, it said, made up $205 million for Rhapsody and $50 million for Population Health. That implies a per-share price of $1.24 to $1.29. The buyback would be at $1.28 after fees. Orion shares soared 27 percent to $1.08 today.
Orion Health went public in late 2014, attracting a $915 million valuation in the initial public offering which sold at $5.70 apiece. The software company had been profitable but chose to forgo earnings in the short-term to build a globally significant business.
In April this year, Orion said revenue missed its guidance as delayed contracts for pushing those sales into the next financial year. At the same time as the profit warning, it announced plans to save as much as $30 million a year from an operational restructure, having already trimmed $10 million of annual costs when it shrank its workforce to 1,050 from 1,200.
No comments yet
MARKET CLOSE: NZ shares gain; a2 hits new record, F&P climbs on patent deal
NZ dollar eases against Aussie on strong jobs data
KiwiSaver funds face unrealised capital gains tax on NZ and Aussie shares
Planning changes need to speed renewables development - Meridian
A guide to the Tax Working Group's 'other' recommendations
MYOB adds 57% more subscribers in 2018 but total online customers still lag Xero's
Investors fear chilling effect as former IRD boss opposes capital gains proposals
Stuff 1H earnings slide but Nine still optimistic of finding buyer
NZ Post achieves first-half revenue growth for the first time since 2015
TeamTalk affirms annual earnings guidance as rising costs dent first-half profit